<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130281">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405976</url>
  </required_header>
  <id_info>
    <org_study_id>PI080346</org_study_id>
    <nct_id>NCT01405976</nct_id>
  </id_info>
  <brief_title>Alternative of Treatment in Obesity Hypoventilation Syndrome</brief_title>
  <official_title>Mid-and Long-term Efficacy of Ventilation Non-invasive and Continuos Positive Airway Pressure in Obesity Hipoventilation Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sociedad Española de Neumología y Cirugía Torácica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sociedad Española de Neumología y Cirugía Torácica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objectives: evaluate the efficacy of noninvasive ventilation (NIV) treatment versus
      continuous positive airway pressure (CPAP) and the &quot;historic&quot; treatment (weight loss and
      oxygen) in Obesity Hipoventilation Syndrome (OHS), with PCO2 and days of hospitalization
      analyzed as a primary variables and percentage of dropouts for medical reasons and mortality
      as operative variables. As secondary variables: Measure functional and clinical improvement
      during sleep and wakefulness, quality of life, and the incidence and evolution of
      cardiovascular events. Objectives secondaries:role of apneogenic sleep events on molecular
      inflammation, endothelial damage and the genesis of diurnal hypercapnia.
      Methods:prospective, randomized controlled trial. Patients with OHS will be divided
      initially into two groups based on their apnea-hypopnea index (AHI) score, &gt;=30 and &lt; 30,
      using conventional polysomnography. The AHI &gt;=30 group will be randomized to CPAP, NIV or
      historic treatment. The AHI &lt;=30 groups will be randomized to NIV or historic treatments.
      Treatment efficacy at the medium- and long-term will be analyzed by comparing groups. The
      role of apneic events and leptin in the genesis of daytime alveolar hypoventilation will be
      analyzed by comparing the daytime PCO2/AHI coefficient between responders and non-responders
      to CPAP treatment, and the evolution of leptin levels in the four branches of the study. The
      role of apneic events in metabolic and biochemical alterations and endothelial dysfunction
      will be analyzed by comparing basal and post-treatment levels of related substances between
      groups, with and without significant AHI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The AHI &gt;=30 group will be analyzed to CPAP, NIV or historic treatment for two mouths.Once
      an evaluation is done during this period, the historical medical treatment will be
      randomized with the NIV/CPAP treatment for a continuation of three years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days of hospitalization</measure>
    <time_frame>at the end of two months and three years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Dropouts for Medical reasons and mortality</measure>
    <time_frame>two months, three years</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Obesity Hypoventilation Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>diet, oxygen, noninvasive ventilation, CPAP</intervention_name>
    <description>diet, oxygen, noninvasive ventilation, CPAP</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 15 and 80 years old.

          -  Absence of moderate or severe chronic obstructive pulmonary disease (COPD).

          -  Absence of neuromuscular, chest wall or metabolic disease which cause daytime
             hypercapnia.

          -  Absence of narcolepsy or restless legs syndrome

          -  Exceed correctly treatment of at least 30 minutes with CPAP/NIV at wakefulness.

        Exclusion Criteria:

          -  Psychophysical incapacity to answer questionnaires.

          -  Patients who are not able to be evaluated by means of quality of life questionnaires
             for suffering restrictive chronic disease previously diagnosed (neoplasy, chronic
             pain of any origin, renal failure, severe chronic obstructive pulmonary disease and
             any other restrictive chronic disease).

          -  Subjects with important chronic nasal obstruction that prevents from using CPAP/NIV.

          -  Informed consent not obtained.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan F Masa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Pedro de Alcántara. Cáceres. Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan F Masa, MD</last_name>
    <phone>34-927-256289</phone>
    <email>fmasa@separ.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara. Servicio Extremeño de Salud</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan F Masa, MD</last_name>
      <phone>34-927-256289</phone>
      <email>fmasa@separ.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>April 19, 2016</lastchanged_date>
  <firstreceived_date>July 3, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sociedad Española de Neumología y Cirugía Torácica</investigator_affiliation>
    <investigator_full_name>Juan F. Masa</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>sleep apneas</keyword>
  <keyword>noninvasive ventilation</keyword>
  <keyword>CPAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Hypoventilation</mesh_term>
    <mesh_term>Obesity Hypoventilation Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
